Zhuoer (Zoey) Xie, MD, MSCR

🚀🔥👉 Exciting News! our study on Risk Prediction for Clonal Cytopenia is out @BloodJournal now! doi.org/10.1182/blood.… #CCRS is easy to use, I hope it proves valuable in your clinics! 👊 Importantly, #CCRS can shape CCUS management and #clinical trial designs!

#FindingFunbiologyFriday The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts ashpublications.org/bloodadvances/…

# TeachingTrendingThursday Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged Leukemia ashpublications.org/blood/article/…

Back from an email-free vacation: 7 years since I last went home, 48 hours of flight, now jet-lagged. Time to return to work, inbox chaos and all. Let’s do this.😊 ✈️📬💼 #BackToWork #PostVacationReset

Durable Responses With Front-Line Rituximab in Autoimmune Cytopenias Associated With Indolent B-Cell Clones #hematology @YoannZdr doi.org/10.1002/ajh.27…

👉👉👉Delighted to share our new collaborative article in @LeukemiaJnl led by 🚨 @MrinalPatnaik & @GMontalbanBravo & @md_padron | @sanamloghavi @kanagalshamanna @doctorpemm @Ramikomrokji @n_gangat nature.com/articles/s4137… | #leusm #TET2

The fast train 🚄in China is so cool, it runs 220miles/h and goes to everywhere! Saves a lot of time from taking the ✈️

Really enjoyed #iwmdsmpn25 in #Lisbon! Great opportunity to know and learn from experts from all over the world🌎 that is amazing incredible effort @Dr_AmerZeidan @ic_MDS 🙏🙏🙏❤️❤️❤️

👏 I saw an interesting anecdote and just looked up the reference. Literally before I was born, an oncologist very succinctly and elegantly summarized how we offer hope to our patients living with cancer... these words are still true today! pubmed.ncbi.nlm.nih.gov/18750361/

Fantastic discussion from @beatalleukemia, Luca Lanino, Robert Hasserjian & Zoey Xie who covered MDS classification and risk stratification🩸🎥🇵🇹 Full discussion will be posted soon on VJHemOnc.com 📱 👀 #iwMDS25 #iwMPN25 #MDSsm

CHIP/CCUS trial design harmonization by @ZhuoerXie (@MoffittNews) @VJHemOnc #iwMDS25 #iwMPN25 #CHIP #CCUS #icMDS

Looking forward to kicking off an amazing @ic_MDS 3rd annual meeting at the #iwMDS2025 #iwMPN2025 with 3 days of packed agenda with top experts & discussions June 27-29. FREE Live streaming available ONLY for health care providers at link @VJHemOnc us06web.zoom.us/webinar/regist…

With the disappointing announcement today by @abbvie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1

So far, every single abstract I’ve listened to at #EHA25 reporting a clinical trial has claimed the study drug was “well tolerated” - despite patients discontinuing therapy due to AEs. One speaker said “well tolerated” >10 times. It’s meaningless. Let data speak for itself.

Some considerations on the dosing of TKIs in CML just published in @BloodPortfolio. @BloodGlobalHema @icmlf @GACancerCenter doi.org/10.1182/blood.…

pt with hx of CLL received BR, obinutuzumab VEN, doing well until profound pancytopenia... NGS: DNMT3A But BMBx below.. Your thoughts?

To attract the best talent, you need to show a drive and desire to be the best.

#TeachingTrendingThursday Grand round at @USC -8hs😃

#WisdomWednesday Who is doing a better job, John vs. Mary? #Simpson's Paradox.

Live from #ASCO25: Moffitt’s Andrew Kuykendall, MD, (@KuykendallMd) presents practice changing results from the VERIFY study, sharing that rusfertide significantly improves outcomes for patients with polycythemia vera. Key takeaways: • Phase 3 VERIFY study compared the hepcidin…

#StorySaturday ⭐️ one of my fav stories from legend @DavidSteensma 👇 The origin and evolution of the term “clone” sciencedirect.com/science/articl…